Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)

¹Relay Therapeutics, Cambridge, Massachusetts;
²Lymphoma Research Foundation, New York, New York;
³King’s College London and Guy’s and St. Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, King’s College London, King’s Health Partners, London, United Kingdom;
⁴Concord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia;
⁵Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts;
⁶Bayer AG, Berlin, Germany;
⁷Department of Medicine, Memorial Sloan Kettering Cancer Center and Weil Cornell Medicine, New York, New York;
⁸Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, Columbia, New York;
⁹Merck and Co, Inc., Kenilworth, New Jersey;
¹⁰Deciphera Pharmaceuticals LLC, Waltham, Massachusetts;
¹¹LYSARC, Pierre Benite, France;
¹²GSK, Collegeville, Pennsylvania;
¹³Autolus Therapeutics, London, United Kingdom;
¹⁴Calyx International, Billerica, Massachusetts;
¹⁵Perlman Advisory Group LLC, Boynton Beach, Florida;
¹⁶Merigold LLC, Branford, Connecticut;
¹⁷Saint John’s Cancer Institute and Tower Imaging Medical Group, Sherman Oaks, California;
¹⁸KEOSYS Medical Imaging, Saint Herblain, France;
¹⁹Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, Illinois; and
²⁰TGEN/City of Hope and Imaging Endpoints Core Lab, Scottsdale, Arizona

For correspondence or reprints, contact Fabien Ricard (fabienricardmd{at}gmail.com).

Statistics from Altmetric.com